{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T19:31:53Z","timestamp":1772566313169,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtct.2024.10.015","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:21:40Z","timestamp":1730740900000},"page":"26.e1-26.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation"],"prefix":"10.1016","volume":"31","author":[{"given":"Chiara","family":"Nozzoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pucillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa Lupo","family":"Stanghellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-2087","authenticated-orcid":false,"given":"Edoardo","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-3083","authenticated-orcid":false,"given":"Silvia","family":"Mangiacavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Parma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Carluccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Galieni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1035-4972","authenticated-orcid":false,"given":"Paolo","family":"Rivela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Isola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0445-9578","authenticated-orcid":false,"given":"Maria","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"Degrandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Boncompagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-524X","authenticated-orcid":false,"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2024.10.015_bib0001","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jtct.2024.10.015_bib0002","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.bbmt.2019.04.026","article-title":"Response to novel drugs before and after allogeneic stem cell transplantation in patients with relapsed multiple myeloma","volume":"25","author":"L\u00f3pez-Corral","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.10.015_bib0003","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/bmt.2017.201","article-title":"Donor T-cell responses and disease progression patterns of multiple myeloma","volume":"52","author":"Eefting","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.015_bib0004","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbmt.2012.10.032","article-title":"Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation","volume":"19","author":"Montefusco","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.015_bib0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3324\/haematol.12184","article-title":"High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma","volume":"93","author":"El-Cheikh","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.10.015_bib0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2024.10.015_bib0007","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.10.015_bib0008","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kroger","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.015_bib0009","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3324\/haematol.2012.069328","article-title":"Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy","volume":"98","author":"Coman","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.10.015_bib0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.10.015_bib0011","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2013.219","article-title":"A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma","volume":"49","author":"Bensinger","year":"2014","journal-title":"Bone Marrow Transplantation"},{"issue":"12","key":"10.1016\/j.jtct.2024.10.015_bib0012","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/bmt.2017.183","article-title":"Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients","volume":"52","author":"Montefusco","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.015_bib0013","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.10.015_bib0014","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.015_bib0015","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.015_bib0016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.015_bib0017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.015_bib0018","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2024.10.015_bib0019","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ejh.12758","article-title":"Outcome of allogeneic transplantation in newly diagnosed and relapsed\/refractory multiple myeloma: long-term follow-up in a single institution","volume":"97","author":"Franssen","year":"2016","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.015_bib0020","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.3324\/haematol.2017.165399","volume":"102","author":"Sobh","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.015_bib0021","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.bbmt.2015.04.020","article-title":"Hematopoietic stem cell transplantation in multiple myeloma: a retrospective study of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"21","author":"Beaussant","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.10.015_bib0022","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.bbmt.2017.05.006","article-title":"Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post-transplantation cyclophosphamide graft-versus-host disease prophylaxis","volume":"23","author":"Castagna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.10.015_bib0023","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"11","key":"10.1016\/j.jtct.2024.10.015_bib0024","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-019-0537-2","article-title":"Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Deutsche Studien gruppe Multiples Myeloma","volume":"33","author":"Knop","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.015_bib0025","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2020.02.020","article-title":"Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: survival outcomes and factors influencing them","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2024.10.015_bib0026","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.015_bib0027","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbmt.2017.10.024","article-title":"Autologous\/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival","volume":"24","author":"Htut","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.015_bib0028","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbmt.2017.09.017","article-title":"Impact of new drugs on the long-term follow-up of upfront tandem autograft-allograft in multiple myeloma","volume":"24","author":"Giaccone","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.015_bib0029","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41409-021-01560-y","article-title":"Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT","volume":"57","author":"Vincent","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.10.015_bib0030","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.bbmt.2020.07.016","article-title":"Prognostic factors for postrelapse survival after ex vivo CD34+-selected (T cell-depleted) allogeneic hematopoietic cell transplantation in multiple myeloma","volume":"26","author":"Gomez-Arteaga","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.015_bib0031","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bmt.1704670","article-title":"Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives","volume":"34","author":"Zeiser","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.015_bib0032","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.exphem.2012.02.009","article-title":"Lenalidomide plus donor lymphocyte infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma","volume":"40","author":"El-Cheikh","year":"2012","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.015_bib0033","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724007449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724007449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T03:40:05Z","timestamp":1767238805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724007449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666636724007449"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.10.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}